face and body and should insist that all defects which follow excision of malignant tumours should be repaired with free grafts, lest a recurrence be masked. This view does not accord with modem surgical practice.
Thirdly, in a-considerable proportion ofpatients for whom an exenteration must be performed, eradication of the tumour will demand the removal of bone in the frontal or ethmoidal regions. This produces extensive bony defects in the medial wall of the orbit, often with free communication into the ethnoidal sinuses, for which a flap repair is essential, there being no wound surface on which to lay a free graft.
Conclusion
In addition to those cases where a flap repair is essential, the method may usefully be employed in other cases of exenteration, and it is the method of choice when periorbital soft tissue and bone must be excised. The advantages are:
(1) The appearance ofthe flap is less objectionable to some patients than is the grafted orbit, since the cavity is much shallower. (2) Once healing is complete, no further toilet of the cavity is required, which is a great advantage to some elderly patients. (3) Healing is usually rapid and complete in about two weeks, when an orbital prosthesis can be fitted in the usual way.
The disadvantages are: (1) It is technically a more difficult operation than the free graft repair and requires experience of fbap design. (2) The method demands the resection of periorbital bone with some alteration of contour in this region. If, therefore, the malignant tumour is wholly confined to the orbital contents (for example an ocular melanoma), it is logical to restrict the deformity to that cavity and to avoid the flap repair. The latter can still be perfomed subsequently if the patient should object to the appearance or to the desquamation of the grafted cavity. J C (1966) If the distinction between the two extreme groups is unclear then the tumour will belong to the intermediate group and it may behave in a variety of ways which cannot be predicted. The behaviour can often be seen to wax and wane.
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Musta&
Before we can have a policy for ana t of lymph nodes we must have some understanding ofthe way the disease behaves.
Although spontaneous regression has, in the past, been reported from time to time, it is only since the recording of a large series of cases that we have begun to put this aspect of malignant disease in perspectiveit is certainly more common than generally realized.
My own experience at Frenchay Hospital (Bodenham 1968), where we now have over 730 cases on the Registry, has shown that in addition to the 3*5% which undergo spontaneous regression, as defined by Everson & Cole (196), 7% smoulder on with clinically manifest disease, either showing little or no change for prolonged periods, or in whom the disease waxes and wanes. In addition we record those cases who, after a prolonged period of clinical freedom from growth, develop a rapidly spreading and fatal disease. Other cases behave in such a rampant manner as to mimic a rapidly fatal miliary tuberculosis.
We are faced, therefore, with a disease of extremes and of every pattern in between. All the indications are that the body possesses, acquires or sometimes loses a complex defence mechanism, partly humoral and partly cellular, which exercises a control over the disease. It cannot be that a standard treatment is right for all the varied patterns but, unfortunately, we are not yet in a position so to predict the outcome as to tailor the treatment specifically for each case. The melanoma is a potential killer, so we must err on the side of caution tending to overtreat some and, at the same time, we must preserve a sense of values and attempt to equate the risks of the disease with the risks of treatment.
As far as I have been able to find out, Sampson Handley, in his 1907 Hunterian Lecture on Malignant Melanoma, was the first to point out in his own words 'a reparative process of round cell infiltration which occurs even in some very malignant growths'. Today if you search through the routine histological sections of primary deposits of malignant melanoma you will see varying degrees of lymphocytic infiltration. This is particularly evident in cases undergoing spontaneous regression and in those which are doing favourably, and we have every reason to welcome their presence.
We have been able to show that demonstrable antibodies can be found in up to 30% of our tumours by immunofluorescence or by agglutination tests.
We have, in our preliminary survey, observed in patients with specific antibodies that the tumours tend, but not always, to grow more slowly than those in which no antibodies can be detected. In other cases which have been followed up and in which a series of recurrences have been observed a loss of antibody has been associated with a definite increase in the speed of tumour development.
We are witnessing in disease the battle in which one or other side may eventually win, or occasionally a battle which settles down to a long cold war. The defence system is complex, the exact relationship of antibody, of possible cytotoxic agents present in the serum as reported by Martin Lewis (1967) , to the role of the lymphocytes and plasma cells is speculative.
When a primary tumour sends living cells along the lymphatics some may get held up in transit and perish, occasionally they may survive in the pipeline, while others reach the lymph nodes and settle. Then one of two things may happen: either the cells grow and, at the same time, the lymph node reacts actively with hyperplasia and the tumour is destroyed, or the lymph node may fail to react and the tumour grows. Sometimes a haemorrhage will occur into the tumour mass with a sudden increase in size of the lymph node; this itself can lead to destruction of tumour and can be followed by a partial or very occasionally complete regression. A growing deposit in a lymph node, even at a very early stage, may itself set up a chain reaction sending further living cells into the lymphatics beyond. This is extremely likely to happen in cases with little or no natural defence.
A lymph node may fail to react to the challenge of tumour cells for one of the following reasons:
(1) The tumour is not antigenic, which is unlikely.
(2) The tumour is antigenic but the attack overwhelms the defence. (3) There may be a specific immunological paralysis to the antigen even though the lymph node is capable of responding to other antigens.
It is against this background that we are trying to build up a blue-print for the management of regional lymph nodes in malignant melanoma and indeed in other cancers which behave in a similar manner.
It would be desirable to help the defence by immunological measures and this might one day be achieved by some form of stimulus combined with a reduction in tumour mass; unfortunately we do not yet know of a reliable way of doing this. The injection of attenuated living tumour has been tried and also non-specific stimulation by vaccination with cowpox or with BCG, both at times with some apparent benefit. Treatment First, it is logical to preserve the reticuloendothelial system intact, so long as it is carrying out its function and has not become involved in the disease. Secondly, it is logical to eliminate any part of the system when it is known to have failed.
In Clinical Stage I cases treatment shouldbe limited to adequate removal of the primary growth. In Clinical Stage II cases a regional lymph-node dissection is carried out because the nodes have failed. If the iliac nodes are involved an ilio-inguinal dissection is completed. Although many workers are attempting to apply statistical evidence to confirm or to condemn the practice of prophylactic lymph-node dissection, all that can be said is that the evidence at present available does not clarify the situation, and it can be surmised, therefore, that there is not going to be any major difference. The operation increases hospital stay by 14-21 days and 25 % of patients suffer in some way from persistent cedema of the foot and ankle. The practice of prophylactic lymph-node dissection is not justified.
1092 Proc. roy. Soc. Med. Volume 62 November 1969 22 Unfortunately the survival after lymph-node involvement is disappointing because the disease has in many cases already spread to other organs such as the brain, the mediastinum and the liver. Nevertheless, it is still worth while.
There are wide differences in the results from different primary sites. When the primary lies between the knee and the ankle the prognosis is favourable, but when the primary is on the back the prognosis is far less favourable and it is improbable that a patient will survive two years after involvement of axillary or inguinal lymph nodes.
There is a place for chemotherapy given under rigidly controlled conditions in selected cases, provided the immuno-defence system is not suppressed too much or for too long. But it is worth remembering that a number of the successful renal transplant cases, who have survived more than two years on immunosuppressive drugs, have developed malignant disease which is attributable to this treatment.
Radiotherapy is not an effective measure for lymph-node metastases.
The melanoma is normally lacking in stroma, it is soft, friable and bleeds easily. Spontaneous hemorrhage is not infrequent and it is not unusual to find, one week, that a patient shows no evidence at all of node involvement but, a week or two later, that a large mass has suddenly appeared in a deposit too small to feel. There is no point in rushing into operation for either the hmmorrhage will have caused widespread dissemination or the growth will have been partly or, very occasionally, wholly destroyed by the bleeding. The hemorrhage will slowly absorb and, so long as the tumour mass continues to subside, there is a case for waiting until it ceases to regress. The argument can also be put forward, thouglh it is purely speculative, that damage to the tumour cells may release antigen, and by-reducing the amount of active tumour may turn the balance in favour of regression.
Summary
Malignant melanoma is a disease of wide extremes and the immuno-defence system is an important factor in influencing the behaviour of each case.
There is no justification for prophylactic lymphnode dissection. Involvement of lymph nodes by tumour is an indication of the failure of the defence mechanism; only 20% of those operated on survive five years and if the primary growth is on the back the chances are that none will survive. Surgery combined with immunotherapy by methods yet to be perfected may prove to be more successful.
A hemorrhage into a deposit is not necessarily serious, may occasionally prove to be beneficial and surgery should not be hurried.
